The Lancet Conference Alerts | Read our late-breaking content from ERS Congress 2025 +... +++++

SERIES Asthma 2025 Free to access with registration https://www.thelancet.com/series-do/asthma-2025?dgcid=hubspot_email_conferencealerts_ers25_asthma25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_YEXmZXtbgUqBGKdUnIzXNJbZeoMYt7a3C7s8wFpgy5hEKcBbl6Vl42_bZ-poxdBvw9xYEtItAKKJIUtIejz92ocYnLw&_hsmi=383112735&utm_content=383112735&utm_source=hs_email ARTICLES Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial Free to access with registration until Oct 9, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00861-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers25&_hsenc=p2ANqtz-_4DnC0RnD_USz9PmYRTqYu__sJ-40CCb_NVB70DlRZ06nXB_kN2X6WyqbVQokfNxN9Y5AbgBlU56756Qd7BjjetbBsZQ&_hsmi=383112735&utm_content=383112735&utm_source=hs_email Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial Free to access with registration https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers25&_hsenc=p2ANqtz--Ga5ruuxUdFSF94OsqVSc2MhACfmQpDgcOCjFMn30uZpDF7nxi_W2AFAZl-xBpT5nBTemLTEnGZdKEa3wraFlnBlA-Uw&_hsmi=383112735&utm_content=383112735&utm_source=hs_email Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial Free to access with registration https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00240-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers25&_hsenc=p2ANqtz-8w7clkcyJ-PKCyY-S3S9MPA27Na09IgqcyjIYa8MuxNiXE8IKUys68NqVNIK4WkVTOe-nT_fQh78UpeezPyXYDzhqkzg&_hsmi=383112735&utm_content=383112735&utm_source=hs_email Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial Free to access with registration https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00287-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers25&_hsenc=p2ANqtz-897nI049LGSDp7Ex8Tqq4n2YP-1r_XY20pCG6B6mQwk28cQMpJhjbL2qdUFeQu_NpFP5S9kDg6a71yP7AbaKT34Z7Ilw&_hsmi=383112735&utm_content=383112735&utm_source=hs_email Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00205-X/fulltext?dgcid=hubspot_email_conferencealerts_ers25&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-8ObDYhIyuYa6p4TaSVu_O-BMCoVUwHyX-6dYoqpD_Y_QV9RgJ5HR77Dd2NdGwnhbOv66dcXU8A-I4ekHsx-a_thd4nRw&_hsmi=383112735&utm_content=383112735&utm_source=hs_email